Suppr超能文献

当代射血分数降低的慢性心力衰竭的药物治疗:CHECK-HF 注册研究。

Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.

机构信息

Department of Cardiology, Maastricht University Medical Center, Maastricht, Limburg, the Netherlands.

Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, Hengelo, the Netherlands.

出版信息

JACC Heart Fail. 2019 Jan;7(1):13-21. doi: 10.1016/j.jchf.2018.10.010.

Abstract

OBJECTIVES

This study investigated adherence to drug therapy guidelines in heart failure (HF) with reduced left-ventricular ejection fraction (LVEF) of <40% (heart failure with reduced ejection fraction [HFrEF]), in which evidence-based treatment has been established.

BACKGROUND

Despite previous surveys of HF, important uncertainties remain regarding guideline adherence in a representative real-world population.

METHODS

A cross-sectional registry in 34 Dutch HF outpatient clinics that included 10,910 patients with the diagnosis of HF was examined. Of that number, 8,360 patients had LVEF <50% (72 ± 12 years of age; 64% male) and were divided into HFrEF (n = 5,701), HF with mid-range LVEF (HFmrEF) with LVEF 40% to 49% (n = 1,574), and those with semiquantitatively measured LVEF but <50% (n = 1,085).

RESULTS

In the HFrEF group, 81% of the patients were treated with loop diuretics, 84% with renin-angiotensin-system (RAS) inhibitors, 86% with β-blockers, 56% with mineralocorticoid-receptor antagonists (MRA), and 5% with I-channel inhibition. Differences in medication use were minor among the 3 groups but were significant among centers. Inability to tolerate the medications was recorded in 9.4% patients taking RAS inhibitors, 3.3% taking β-blockers, and 5.4% taking MRAs. Median loop diuretic dose was 40 mg of furosemide equivalent, RAS inhibitor dose 50% of target, β-blocker dose 25% of target, and MRA dose 12.5 mg of spironolactone equivalent. Elderly patients were treated predominantly with diuretics and less often with RAS inhibitors, β-blockers, and MRAs.

CONCLUSIONS

This large contemporary HF registry showed a relatively high use of evidence-based treatment, particularly in younger patients. However, the average dose of evidence-based medication was still lower than recommended by guidelines. Furthermore, the more recently introduced I-channel inhibition has hardly been adopted. There is ample room for improvement of HFrEF therapy, even more than 25 years after convincing evidence that HFrEF treatment leads to better outcome.

摘要

目的

本研究旨在调查射血分数降低的心衰(HFrEF)[左心室射血分数(LVEF)<40%]患者的药物治疗依从性,因为 HFrEF 有明确的循证治疗方案。

背景

尽管此前已经对心衰进行了调查,但在具有代表性的真实世界人群中,指南依从性仍存在重要的不确定性。

方法

本研究纳入了 34 家荷兰心衰门诊的 10910 例心衰患者,对其中 LVEF<50%(72±12 岁;64%为男性)的 8360 例患者进行了分析。这 8360 例患者被分为 HFrEF(n=5701)、射血分数中间范围的心衰(HFmrEF)[LVEF 为 40%至 49%,n=1574]和 LVEF 半定量测量<50%但明确诊断为心衰的患者(n=1085)。

结果

在 HFrEF 组中,81%的患者接受了袢利尿剂治疗,84%接受了肾素-血管紧张素系统(RAS)抑制剂治疗,86%接受了β受体阻滞剂治疗,56%接受了盐皮质激素受体拮抗剂(MRA)治疗,5%接受了 I 通道抑制治疗。3 组之间的药物使用差异较小,但中心之间存在显著差异。接受 RAS 抑制剂治疗的患者中有 9.4%、接受β受体阻滞剂治疗的患者中有 3.3%和接受 MRA 治疗的患者中有 5.4%报告出现不能耐受药物的情况。袢利尿剂的中位剂量为 40mg 呋塞米当量,RAS 抑制剂剂量为目标剂量的 50%,β受体阻滞剂剂量为目标剂量的 25%,MRA 剂量为螺内酯当量的 12.5mg。老年患者主要接受利尿剂治疗,较少接受 RAS 抑制剂、β受体阻滞剂和 MRA 治疗。

结论

这项大型当代心衰注册研究显示,基于证据的治疗方法的使用率相对较高,尤其是在年轻患者中。然而,基于证据的药物的平均剂量仍低于指南推荐的剂量。此外,最近引入的 I 通道抑制几乎没有被采用。即使在有明确证据表明 HFrEF 治疗可改善预后 25 年之后,HFrEF 的治疗仍有很大的改进空间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验